Home > Boards > Stock Clubs > Long-Term > Billionaire Boys Club Member Forum (BBCMF)

$GTCH News Out: GEN II Prototype qTerm Includes

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
budfoxfun Member Profile
Member Level 
Followed By 899
Posts 356,022
Boards Moderated 11
Alias Born 06/24/11
160x600 placeholder
Gilead Gets FDA Approval for Remdesivir for Some Non-Hospitalized Patients
By Josh Beckerman
Top Company News of the Day
Netflix Ends Down Nearly 22%, Worst Performer in the S&P 500 and Nasdaq 100 Today -- Data Talk
2-Year Treasury Yield Rises to 0.993% This Week -- Data Talk
10-Year Treasury Yield Falls to 1.747% This Week -- Data Talk
30-Year Treasury Yield Falls to 2.062% This Week -- Data Talk
Wheat Falls as U.S.-Russia Negotiations Continue - Daily Grain Highlights
Front Month Nymex Natural Gas Fell 6.17% This Week to Settle at $3.9990 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 0.97% This Week to Settle at $2.4424 -- Data Talk
GDP Seen +5.8% in 4Q -- Data Week Ahead
Canada's Omicron Infections May Have Peaked But Hospitalizations Rise, Health Officer Says
Coinbase Global Down Over 12%, on Track for Record Low Close and Record Percent Decrease -- Data Talk
EURO STOXX 50 Index Ends the Week 1.00% Lower at 4229.56 -- Data Talk
CAC 40 Index Ends the Week 1.04% Lower at 7068.59 -- Data Talk
STOXX Europe 50 Index Ends the Week 0.44% Lower at 3781.98 -- Data Talk
STOXX Europe 600 Index Ends the Week 1.40% Lower at 474.44 -- Data Talk
FTSE 100 Index Ends the Week 0.65% Lower at 7494.13 -- Data Talk
DAX Ends the Week 1.76% Lower at 15603.88 -- Data Talk
FTSE 100 Ends the Week Lower, Losing Year-to-Date Gains
Ecolab Down Nearly 6%, on Track for Largest Percent Decrease Since July 2020 -- Data Talk
Intuitive Surgical Down Nearly 7%, on Pace for Largest Percent Decrease Since April 2020 -- Data Talk
GM Expanding Production of Electric Motor Parts in NY State
Walt Disney Worst Performer in the DJIA So Far Today -- Data Talk
Glaxo Unit Valuation Boost Looks Less Likely as Unilever Walks -- Market Insight
budfoxfun Member Level  Thursday, 05/27/21 08:04:32 AM
Re: None
Post # of 560369 
$GTCH News Out: GEN II Prototype qTerm Includes a Series of Enhancements

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT”, or the “Company”) via GBT Tokenize Corp, completed generation II of its qTerm device. The GEN II release is a second version that includes a series of enhancements that target higher measurement accuracy, reliability and compatibility with a broader spectrum of users usage behavior. GBT's qTerm, a human vitals intelligent device is aimed to measure human vitals with a touch of a finger. Based on GEN I prototype testing, debugging and study, GBT’s concluded GEN II version to significantly advance the device’s general population compatibility. qTerm’s second release includes body temperature, blood oxygen and heart rate vitals with higher stability, and consistency to cover wider spectrum of users measurement habits. The device’s sensors were physically re-located to more efficient positions to enable best and consistent results. An additional coprocessor chip was installed to provide an advanced adjusting algorithm to support broader user’s measuring habits, compensating for different inputs and providing consistent results. Similar to the GEN I version, the GEN II device will be accompanied by a smartphone app and synchronized web application to keep a history and provide analytics for user's records at a later phase. The web application will be providing a geographical location and proximity alert to assist with potential health risks. GEN II series of modifications are done as part of the Company’s preparations for an FDA certification to classify qTerm as a medical device to be marketed and sold in the US. The certification process will be also aimed to define the device for telemedicine purposes enabling remote vitals results to be sent to clinics and hospitals for physicians review in real time. qTerm’s GEN II device is currently under testing for technical performance and commercial look-and-feel features evaluation.

"We are proud to announce the completion of our Gen II qTerm human vital device. We implemented a series of improvements in qTerm’s second release to achieve higher performance, accuracy, and user’s compatibility level. We put extra emphasis on the device ease of use, and user friendliness aspects. The device is currently under technical performance testing and commercial features look-and-feel evaluations. We strongly believe that qTerm can be an efficient, affordable health device in every household to assist with general health monitoring and early detection of symptoms and concerns. We are ever thriving to improve the device’s performance and capabilities, bringing it to the highest standards and regulations to enable people maintaining healthy life style," stated Danny Rittman, the Company’s Chief Technology Officer.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences